Clinical trial Recruiting at 1 site Observational Ages 18 to 99

NAIF 2.0: See if glymphatic flow changes after dAVF treatment

Official title: NAIF 2.0 - COGNIFY: Cognitive Impairment in Patients With Intracranial Dural Arteriovenous Fistulae: Exploration & Understanding

Run by Hospital Universitari Vall d'Hebron Research Institute · NCT07824297 · Data updated 2026-11-12

This study tests whether the brain’s waste-clearance system changes after endovascular treatment for intracranial dural arteriovenous fistulas in adults.

Quick facts

Study typeObservational
Ages18 Years to 99 Years
SexAll
Enrollment20 (estimated)
SponsorHospital Universitari Vall d'Hebron Research Institute
Academic / other
Locations3 sites (Bologna and 2 other locations)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedAugust 1, 2028
Study endsAugust 1, 2029
Registry record updatedSeptember 17, 2026
Trial IDNCT07824297 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–99 with an angiographically confirmed unruptured intracranial dAVF who are planned for endovascular embolization and can undergo MRI.

Probably not a fit

Patients who do not show changes in glymphatic imaging markers or who do not have cognitive symptoms may not experience measurable benefits in this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares brain MRI measurements taken before and about six months after endovascular embolization for unruptured intracranial dAVFs. The goal is to see if glymphatic system function, as seen on advanced diffusion-weighted MRI, improves following treatment. Researchers will analyze imaging markers related to perivascular spaces and brain clearance to understand potential links between venous drainage, embolization, and cognitive outcomes. Participants are adults undergoing treatment as part of standard care and will contribute imaging data within routine clinical workflows. The study builds on prior NAIF findings suggesting cognitive improvements after embolization and seeks to elucidate underlying mechanisms.

Why it matters

Potential benefit: If successful, findings could clarify how dAVF treatment affects brain waste clearance and potentially relate to cognitive outcomes after embolization.

How similar studies have gone: Previous NAIF work suggested possible cognitive improvements after embolization, but the glymphatic mechanistic link remains exploratory and not yet proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged 18 to 99 years.
* Angiographically confirmed diagnosis of unruptured intracranial dAVF.
* Candidate for endovascular embolization treatment with curative intent.
* Able to undergo Brain MRI.

Exclusion Criteria:

* Contraindication to angiographic embolization procedures.
* Acute intracranial haemorrhage secondary to dAVFs rupture and/or venous hypertension.
* Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study, other contraindications to MRI such as certain metallic implants.

Where it's running

  • Hospital Universitario Vall D'Hebron
    Barcelona, Spain
    Recruiting
  • Università di Bologna
    Bologna, Italy
    Not yet recruiting
  • University of Oxford
    Oxford, United Kingdom
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.